C O M M U N I C A T I O N S
Figure 3. Cellular uptake studies of 1 in PR(+) and PR(-) cells. Compound 1 showed more uptake in PR(+) cells than PR(-) cells.
Table 1. T1 (seconds) of Cells at 9.4T, Where Cells Were Treated
References
with 50 µM of Each Compound and Incubated for 16 ha
(1) (a) Braselmann, S.; Graninger, P.; Busslinger, M. Proc. Natl. Acad. Sci.
U.S.A. 1993, 90, 1657-1661. (b) Jenster, G.; Spencer, T.; Burcin, M.;
Tsai, S. Y.; Tsai, M.-J.; O’Malley, B. W. Proc. Natl. Acad. Sci. U.S.A.
1997, 94, 7879-7884. (c) Osterwalder, T.; Yoon, K. S.; White, B. H.;
Keshishian, H. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 12596-12601.
(2) Zacharias, D. A.; Baird, G. S.; Tsien, R. Curr. Opin. Neurobiol. 2000,
10, 416-421.
cells/compounds
T1 (s)
PR(+) cells treated with RU-486
PR(-) cells treated with RU-486
PR(+) cells treated with 1
PR(-) cells treated with 1
media
3.18 ( 0.11
2.90 ( 0.11
2.06 ( 0.16
2.30 ( 0.30
3.03 ( 0.16
(3) (a) Jacobs, R. E.; Cherry, S. R. Curr. Opin. Neurobiol. 2001, 11, 621-
629. (b) Meade, T. J.; Taylor, A. K.; Bull, S. R. Curr. Opin. Neurobiol.
2003, 13, 597-602. (c) Toth, E.; Helm, L.; Merbach, A. E. In
ComprehensiVe Coordination Chemistry II, 2nd ed.; McCleverty, J. A.,
Meyer, T. J., Eds.; Elsevier: St. Louis, 2004; Vol. 9, pp 841-881.
(4) Allen, M. J.; Meade, T. J. In Metal Ions in Biological Systems; Sigel, A.,
Sigel, H., Eds.; Marcel and Decker, Fontis Media: New York, 2004; Vol.
42, pp 1-38.
(5) (a) Parker, D.; Williams, J. A. G. J. Chem. Soc., Dalton Trans. 1996,
3613-3628. (b) Peters, J. A.; Huskens, J.; Raber, D. J. Prog. Nucl. Magn.
Reson. Spectrosc. 1996, 28, 283-350. (c) Aime, S.; Fasano, M.; Terreno,
E. Chem. Soc. ReV. 1998, 27, 19-29. (d) Aime, S.; Botta, M.; Fasano,
M.; Terreno, E. Acc. Chem. Res. 1999, 32, 941-949.
(6) Caravan, P.; Ellison, J. J.; McMurry, T. J.; Lauffer, R. B. Chem. ReV.
1999, 99, 2293-2352.
a T1-weighted spin-echo MR images are provided in the Supporting
Information.
treated cells appear bright and have approximately 40% shorter T1;
on the contrary, RU-486 treated cells and media have longer T1.
The 40% T1 difference should provide sufficient contrast for in
vivo imaging.8a
In summary, we have synthesized the first steroid hormone-
MR contrast agent conjugate designed to track cell signaling
processes upon binding to a transcriptional system. The compound
successfully crossed cell membranes and modulated gene transcrip-
tion. The high relaxivity of 1 showed the contrast enhancement at
low concentrations in vitro and did not significantly affect cell
viability. By combining a transcriptional system and a noninvasive
imaging technology, such as MRI, it should be possible to
simultaneously and quantitatively activate transcription of reporter
genes and image genetically defined neuronal circuits that express
GAL4-PR.1,14 This should facilitate functional neuroanatomical
studies, such as electrophysiology and neuronal tract tracing. We
are optimizing the molecular architecture and the incubation
conditions to improve the binding affinity and the selective
retention.
(7) Lauffer, R. B. Chem. ReV. 1987, 87, 901-927.
(8) (a) Louie, A. Y.; Huber, M. M.; Ahrens, E. T.; Rothbacher, U.; Moats,
R.; Jacobs, R. E.; Fraser, S. E.; Meade, T. J. Nat. Biotechnol. 2000, 18,
321-325. (b) Li, W. H.; Parigi, G.; Fragai, M.; Luchinat, C.; Meade, T.
J. Inorg. Chem. 2002, 41, 4018-4024. (c) Allen, M. J.; MacRenaris, K.
W.; Venkatasubramanian, P. N.; Meade, T. J. Chem. Biol. 2004, 11, 301-
307.
(9) (a) Williams, S. P.; Sigler, P. B. Nature, 1998, 393, 392-396. (b) Bursi,
R.; Groen, M. B. Eur. J. Med. Chem. 2000, 35, 787-796. (c) So, S.-S.;
Van Helden, S. P.; Van Geerestein, V. J.; Karplus, M. J. Chem. Inf.
Comput. Sci. 2000, 40, 762-772. (d) Madauss, K. P.; Deng, S.-J.; Austin,
R. J. H.; Lambert, M. H.; McLay, I.; Pritchard, J.; Short, S. A.; Stewart,
E. L.; Uings, I. J.; Williams, S. P. J. Med. Chem. 2004, 47, 3381-3387.
(10) Duggan, M. E.; Imagire, J. S. Synthesis 1989, 131-132.
(11) Compound 3 was synthesized as previously reported for a bridged steroid
synthesis: Mikola, H.; Hanninen, E. Bioconjugate Chem. 1992, 3, 182-
186.
Acknowledgment. We thank Scott Fraser for helpful discus-
sions, Keith MacRenaris for ICP-MS analysis, Steve Bull for image
acquisition and T1 analysis, and Ken Korach for providing PRE-
luciferase. This work is supported by the National Institutes of
Health (5RO1 A147003, DOD 91008600, and PO1HD021921), and
by Northwestern University Reproductive Biology Training Grant
T32 HD007068.
(12) Two different isomers (syn/anti) of 3-oxime compound were synthesized
when RU-486 was refluxed with hydroxylamine hydrochloride in pyridine.
The isomers were separated by column chromatography on silica using
the eluent of hexane:ethyl acetate ) 1:1.
(13) Eliminating isomerism (syn/anti at C3) may enhance the binding affinity.
We attempted to separate the isomeric mixture to determine (if any) the
effect that a purified isomer may have; however, we were unsuccessful.
(14) (a) Stern, C. D.; Fraser, S. E. Nat. Cell Biol. 2001, 3, E216-E218. (b)
Duffy, J. B. Genesis 2002, 34, 1-15.
Supporting Information Available: Experimental procedures,
spectroscopic data, and T1-weighted MR images. This material is
JA051294X
9
13166 J. AM. CHEM. SOC. VOL. 127, NO. 38, 2005